EUVIMEDEUVIMED entdecken
Crossref

Mass spectrometry‐based metabolomics reveals metabolism of molnupiravir may lead to metabolic disorders and hepatotoxicity

Jiahui Chen, Liqiong Chen, Bin Li, Qi Zhao, Yan Cheng, Dongmei Yan, Hongning Liu, Fei Li

Biomedical Chromatography · 2024

DOI: 10.1002/bmc.5996 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, 2024. Verfasst von Jiahui Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Academician Workstation, Jiangxi University of Chinese Medicine, Nanchang, China. Hauptthemen laut MEDLINE: Metabolomics, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Key Research and Development Program of China, West China Hospital, West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molnupiravir (MO) is a pyrimidine nucleoside anti‐SARS‐CoV‐2 drug. MO treatment could cause mild liver injury. However, the underlying mechanism of MO‐induced liver injury and the metabolic pathway of MO in vivo are unclear. In this study, metabolomics analysis and molecular biology methods were used to explore these issues. Through metabolomics analysis, it was found that the homeostasis of pyrimidine, purine, lysophosphatidylcholine (LPC), and amino acids in mice was destroyed after MO treatment. A total of 80 changed metabolites were detected. Among these changed metabolites, 4‐ethylphenyl sulfate, dihydrouracil, and LPC 20:0 was related to the elevation of alkaline phosphatase (ALP), interleukin‐6 (IL6), and nuclear factor kappa‐B (NF‐κB). The levels of 4‐ethylphenyl sulfate, dihydrouracil, and LPC 20:0 in plasma were positively correlated with their levels in the liver, suggesting that these metabolites were associated with MO‐induced liver injury. MO treatment could increase NHC and cytidine levels, activate cytidine deaminase (CDA), and increase LPC levels. CDA and LPC could increase the mRNA expression level of toll‐like receptor (TLR). The current study indicated that the elevation of hepatic TLR may be an important reason for MO leading to the liver injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetabolomicsChemical and Drug Induced Liver InjuryAnimalsMiceMaleAntiviral AgentsLiverMetabolomeMass SpectrometryUridineMice, Inbred C57BLCOVID-19 Drug TreatmentCytidineHydroxylamines

Stichwörter der Autor:innen

COVID‐19liver injurymetabolomicsmolnupiravirpyrimidine metabolism

Substanzen

molnupiravirAntiviral AgentsUridineCytidineHydroxylamines

Autor:innen und Institutionen

  • Academician Workstation, Jiangxi University of Chinese Medicine, Nanchang, China.
  • Department of Gastroenterology & Hepatology, Laboratory of Hepato-intestinal Diseases and Metabolism, Frontiers Science Center for Disease-Related Molecular Network, and State Key Laboratory of Respiratory Health and Mu…

Förderung

  • National Key Research and Development Program of China
  • West China Hospital
  • West China Hospital, Sichuan University

Zitieren

APA

Chen, J., Chen, L., Li, B., Zhao, Q., Cheng, Y., Yan, D., Liu, H., & Li, F. (2024). Mass spectrometry‐based metabolomics reveals metabolism of molnupiravir may lead to metabolic disorders and hepatotoxicity. Biomedical Chromatography. https://doi.org/10.1002/bmc.5996

Vancouver

Chen J, Chen L, Li B, Zhao Q, Cheng Y, Yan D, et al. Mass spectrometry‐based metabolomics reveals metabolism of molnupiravir may lead to metabolic disorders and hepatotoxicity. Biomedical Chromatography. 2024. doi:10.1002/bmc.5996

BibTeX
@article{Chen2024,
  author = {Chen, Jiahui and Chen, Liqiong and Li, Bin and Zhao, Qi and Cheng, Yan and Yan, Dongmei and Liu, Hongning and Li, Fei},
  title = {Mass spectrometry‐based metabolomics reveals metabolism of molnupiravir may lead to metabolic disorders and hepatotoxicity},
  journal = {Biomedical Chromatography},
  year = {2024},
  doi = {10.1002/bmc.5996}
}
Kostenlos starten →